GLYX-13 CAS 117928-94-6

1. The starting material introduces or replaces functional groups through substitution reactions. This step is usually carried out under the action of specific solvents and catalysts, ensuring that functional groups can accurately and efficiently connect to the raw material molecules. The selectivity of substitution reactions is crucial as it directly affects the likelihood of subsequent reactions and the purity of the products.

2. Addition reactions are used to construct new chemical bonds and molecular frameworks. In this step, the raw material molecules react with specific reagents to expand the molecular structure by forming new carbon carbon bonds or carbon heteroatom bonds. The conditions for addition reactions, such as temperature, pressure, and reaction time, need to be precisely controlled to ensure efficient reaction and product stability.

3. The cyclization reaction is a crucial step in the synthesis of rapatinib, which is responsible for converting linear molecules into compounds with specific cyclic structures. This reaction typically involves intramolecular rearrangement or closure, requiring the selection of appropriate catalysts and reaction conditions to promote the formation of cyclic structures. The success or failure of the cyclization reaction is directly related to the structure and activity of the final product.

After each reaction stage is completed, careful separation and purification of the reaction products are required. This typically involves using methods such as column chromatography, crystallization, or distillation to remove unreacted raw materials, catalysts, solvents, and byproducts. This step is crucial for ensuring the smooth progress of the next reaction, as the presence of impurities may interfere with subsequent reactions, leading to a decrease in product purity or the generation of unnecessary by-products.

Through this series of reactions and purification steps, the molecular framework of rapatinib can be gradually constructed, and ultimately a high-purity target product can be obtained. Although this method involves multiple steps and complex operations, its high selectivity and controllability make it an effective method for synthesizing complex organic molecules such as rapatinib.

Meanwhile, with the continuous development of synthetic chemistry and separation technology, this method is also constantly being optimized and improved, providing a more efficient and environmentally friendly approach for the synthesis of drugs such as GLYX-13.

In the 1980s, the research team led by Joseph Moskal at Northwestern University in the United States focused on the mechanism of NMDA receptors in learning and memory, and developed the monoclonal antibody B6B21 targeting this receptor.

From 1987 to 1991, the team confirmed that B6B21 could specifically bind to the NMDA receptor and regulate its function, laying a foundation for the subsequent development of peptide mimetics.

At that time, the NMDA receptor was known to be associated with depression and cognitive impairment, yet safe and selective modulators were lacking, making the development of targeted modulators a research hotspot.

In the late 1990s, the team cloned the variable region sequence of the light chain of antibody B6B21 and found that the fragment QQHYSTPPT possessed receptor-binding activity.

Based on this, a series of short peptides were synthesized, and GLYX-13 (Thr-Pro-Pro-Thr-NH₂) composed of four amino acids was screened out. As the 13th active peptide in this series, it was named GLYX-13.

Acting as a partial agonist at the glycine site of the NMDA receptor, it can cross the blood-brain barrier, enhance BDNF release, exert rapid onset of action, and cause no hallucinogenic side effects. Structural optimization and patent application were completed after 2000.

In 2015, Naurex Inc. was acquired by Allergan, and GLYX-13 was renamed Rapastinel. In 2016, it was granted FDA Breakthrough Therapy Designation for adjuvant treatment of treatment-resistant depression.

Phase II clinical trials from 2015 to 2018 verified its remarkable rapid antidepressant efficacy; however, Phase III trials in 2019 failed to meet clinical endpoints, suspending further development. Even so, it has provided critical insights for the subsequent research of NMDA receptor-targeted antidepressants.